Comparison of the Protective Efficacy of Flublok Quadrivalent Versus Licensed Inactivated Influenza Vaccine (IIV4) in Healthy, Medically Stable Adults ≥50 Years of Age

Trial Profile

Comparison of the Protective Efficacy of Flublok Quadrivalent Versus Licensed Inactivated Influenza Vaccine (IIV4) in Healthy, Medically Stable Adults ≥50 Years of Age

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 29 Oct 2017

At a glance

  • Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Protein Sciences Corporation
  • Most Recent Events

    • 22 Jun 2017 Results published in the New England Journal of Medicine
    • 22 Jun 2017 Results published in a Protein Sciences Corporation media release.
    • 22 Jun 2017 Results published in the New England Journal of Medicine, according to a Protein Sciences Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top